Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).
Hirohito Tada
Honoraria - Kyowa Hakko Kirin
Koji Takeda
No relevant relationships to disclose
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Isamu Okamoto
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Tetsuya Mitsudomi
Consultant or Advisory Role - Kyowa Hakko Kirin
Honoraria - AstraZeneca
Yukito Ichinose
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Kenji Sugio
Honoraria - AstraZeneca; Kyowa Hakko Kirin
Masahiro Tsuboi
Honoraria - AstraZeneca
Yoichi Nakanishi
Honoraria - AstraZeneca; Kyowa Hakko Kirin